Technical Analysis for BIIB - Biogen Idec Inc.

Grade Last Price % Change Price Change
grade F 227.93 -0.39% -0.88
BIIB closed up 1.07 percent on Monday, April 22, 2019, on 73 percent of normal volume.

Earnings due: Apr 24

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical BIIB trend table...

Date Alert Name Type % Chg
Oversold Stochastic Weakness -0.38%
Hammer Candlestick Bullish 0.68%
Lizard Bullish Bullish Day Trade Setup 0.68%
Down 3 Days in a Row Weakness 0.68%
Down 4 Days in a Row Weakness 0.68%
Oversold Stochastic Weakness 0.68%
Stochastic Reached Oversold Weakness 0.32%
Down 3 Days in a Row Weakness 0.32%
Oversold Stochastic Weakness 0.32%
Wide Bands Range Expansion -0.35%

Older signals for BIIB ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company's products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company's Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
Medicine Biotechnology Pain Immunology Monoclonal Antibodies Alzheimer's Disease Multiple Sclerosis Specialty Drugs Chronic Lymphocytic Leukemia Autoimmune Disorders Immunosuppressants Isis Hemophilia Neurodegenerative Diseases Spinal Muscular Atrophy Treatment Of Hemophilia Biogen Idiopathic Pulmonary Fibrosis NHL Lupus Nephritis Clinical Trial Products
Is BIIB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 388.67
52 Week Low 216.12
Average Volume 2,432,515
200-Day Moving Average 319.5937
50-Day Moving Average 283.0414
20-Day Moving Average 232.7895
10-Day Moving Average 232.955
Average True Range 7.767
ADX 36.5
+DI 18.4862
-DI 39.6341
Chandelier Exit (Long, 3 ATRs ) 220.779
Chandelier Exit (Short, 3 ATRs ) 239.421
Upper Bollinger Band 242.8182
Lower Bollinger Band 222.7608
Percent B (%b) 0.3
BandWidth 8.61611
MACD Line -15.0998
MACD Signal Line -17.3256
MACD Histogram 2.2257
Fundamentals Value
Market Cap 48.38 Billion
Num Shares 211 Million
EPS 15.24
Price-to-Earnings (P/E) Ratio 15.01
Price-to-Sales 5.55
Price-to-Book 5.61
PEG Ratio 2.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 237.23
Resistance 3 (R3) 237.41 234.80 235.82
Resistance 2 (R2) 234.80 232.65 234.70 235.35
Resistance 1 (R1) 231.80 231.33 233.30 231.62 234.89
Pivot Point 229.19 229.19 229.94 229.09 229.19
Support 1 (S1) 226.19 227.04 227.69 226.01 222.73
Support 2 (S2) 223.58 225.72 223.48 222.27
Support 3 (S3) 220.58 223.58 221.80
Support 4 (S4) 220.40